Cepharanthine exerts antitumor activity on oral squamous cell carcinoma cell lines by induction of p27Kip1

Anticancer Research

Volumn 23, Issue 2 B, 2003, Pages 1441-1448

  Harada, Koji ^a   Supriatno, ^a   Yamamoto, Shin ^a   Kawaguchi, Shin Ichi ^a   Yoshida, Hideo ^a   Sato, Mitsunobu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Apoptosis; Cepharanthine; G1 arrest; Oral squamous cell carcinoma; p27Kip1

Indexed keywords

CEPHARANTHINE; CYCLIN E; DNA FRAGMENT; PROTEIN; PROTEIN P27; PROTEIN SKP 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE G1 PHASE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; MOUTH CARCINOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN INDUCTION; SQUAMOUS CELL CARCINOMA; STAINING; WESTERN BLOTTING;

ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA FRAGMENTATION; DRUG SCREENING ASSAYS, ANTITUMOR; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOUTH NEOPLASMS; NEOPLASM PROTEINS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037900693     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Tomita M, Fujitani K and Aoyagi Y: Synthesis of dl-cepharanthine. Tetrahedron Lett 13: 1201-06, 1967.
2. Saito R, Tsuchiya S, Ishizuka T et al.: Clinical effects of cepharanthine (Ceph.) on leukopenia by chemotherapy in lung cancer patients. J Jpn Soc Cancer Ther 24: 4587-93, 1989.
3. Ono M: Antitumor effect of cepharanthine: activation of regional lymph node lymphocytes by intratumoral administration. Clin Immunol 19: 1061-64, 1987.
4. Morioka S, Ono M, Tanaka N and Orita K: Synergistic activation of rat alveolar macrophages by cepharanthine and OK-432. Jpn J Cancer Chemother 12: 1407-1407, 1985.
5. Asaumi J, Kawasaki S, Nishikawa K, Kuroda M and Hiraki Y: Effects of hyperthermia and cepharanthine on adriamycin accumulation with change in extracellular pH. Int J Hyperthermia 11: 27-35, 1995.
6. Nishikawa K, Asaumi J, Kawasaki S, Kuroda M, Takeda Y and Hiraki Y: Influence of cepharanthine on the intracelluar accumulation of adriamycin in normal liver cells and spleen cells of mice in vitro and in vivo. Anticancer Res 17: 3617-22, 1997.
7. Hotta T, Tanimura H, Yamaue H et al.: Modulation of multidrug resistance by cepharanthine in fresh human gastrointestinal tumor cells. Oncology 54: 153-57, 1997.
8. Hotta T, Tanimura H, Yamaue H et al.: Synergistic effects of tamoxifen and cepharanthine for circumventing the multidrug resistance. Cancer Lett 107: 117-23, 1996.
9. Furusawa S, Wu J, Fujimura T et al.: Cepharanthine inhibits proliferation of cancer cells by inducing apoptosis. Meth Find Exp Clin Pharmacol 20: 87-89, 1998.
10. Harada K, Bando T, Yoshida H and Sato M: Characteristics of antitumour activity of cepharanthine against a human adenosquamous cell carcinoma cell line. Oral Oncol 37: 643-51, 2001.
11. Kawamata H, Nakashiro K, Uchida D, Harada K, Yoshida H and Sato M: Possible contribution of active MMP2 to lymph-node metastasis and secreted cathepsin L to bone invasion of newly established human oral-squamous-cancer cell lines. Int J Cancer 70: 120-7, 1997.
12. Kip1 induces growth arrest and apoptosis in an oral cancer cell line. Oral Oncol (in press).
13. Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated calorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-42, 1987.
14. Koff A, Ohtsuki ME, Polyak K, Roberts J and Massagué, J: Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF β. Science 257: 1689-94, 1993.
15. Abe T, Inamura S and Akasu M: Effect of cepharanthin on the lethality and cardiovascular disorder by Mamushi, Agkistrodon halys blomhoffi, snake venom. Nippon Yakurigaku Zasshi 98: 327-36, 1991. Japanese.
16. Asaumi J, Nishikawa K, Matsuoka H et al.: Direct antitumor effect of cepharanthine and combined effect with adriamycin against Ehrlich ascites tumor in mice. Anticancer Res 15: 67-70, 1995.
17. kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85: 707-20, 1996.
18. St Croix B, Florenes VA, Rak JW et al.: Impact of the cyclin-dependent kinase inhibitor p27kip1 on resistance of tumor cells to anti-cancer agents. Nature Med 2: 1204-1210, 1996.
19. Katayose Y, Kim M, Rakkar ANS, Li Z, Cowan KH and Seth P: Promoting apoptosis: a novel activity associated with the cyclindependent kinase inhibitor p27. Cancer Res 57: 5441-5445, 1997.
20. Ophascharoensuk V, Fero ML, Hughes J, Roberts JM and Shankland SJ: The cyclin-dependent kinase inhibitor p27kip1 safeguards against inflammatory injury. Nature Med 4: 575-580, 1998.
21. Durand B, Gao FB and Raff M: Accumulation of the cyclindependent kinase inhibitor p27/kip1 and the timing of oligodendrocyte differentiation. EMBO J 16: 306-317, 1997.
22. Kawamata N, Morosetti R, Miller CW et al.: Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 55: 2266-2269, 1995.
23. Catzavelos C, Bhattacharya N, Ung YC et al.: Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nature Med 3: 227-230, 1997.
24. Esposito V, Baldi A, De Luca A et al.: Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57: 3381-3385, 1997.
25. Mori M, Mimori K, Shiraishi T et al.: p27 expression and gastric carcinoma. Nature Med 3: 593, 1997.
26. Mineta H, Miura K, Suzuki I et al.: Low p27 expression correlates with poor prognosis for patients with oral tongue squamous cell carcinoma. Cancer 85: 1011-1017, 1999.
27. Venkatesan TK, Kuropkat C, Caldarelli DD et al.: Prognostic significance of p27 expression in carcinoma of the oral cavity and oropharynx. Laryngoscope 109: 1329-1333, 1999.
28. Kudo Y, Takata T, Yasui W et al.: Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is an indicator of malignant behavior in oral squamous cell carcinoma. Cancer 83: 2447-2455, 1998.
29. Carrano AC, Eytan E, Hershko A and Pagano M: Skp2 is required for the ubiquitin-mediated degradation of the Cdk-inhibitor p27. Nat Cell Biol 1: 193-199, 1999.
30. Sutterluty H, Chatelain E, Marti A et al.: p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1: 207-214, 1999.
31. Tsvetkov LM, Yeh KH, Lee, S, Sun H and Zhang H: p27Kip1 ubiquitination and degradation is regulated by the SCFSkp2 complex through phosphorylated Thr187 in p27. Curr Biol 9: 661-664, 1999.
32. Zhang H, Kobayashi R, Galaktionov K and Beach D: p19Skp-1 and p45Skp-2 are essential elements of the cyclin A-Cdk2 S phase kinase. Cell 82: 915-925, 1995.
33. Nakayama K, Nagahama H, Minamishima Y et al.: Targeted disruption of Skp2 results in accumulation of cyclin E and p27 Kip1, polyploidy and centrosome overduplication. EMBO J 19: 2069-2081, 2000.
34. Craig C, Wersto R, Kim M et al.: A recombinant adenovirus p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene 14: 2283-2289, 1997.
35. Hiromura K, Pippin JW, Fero ML, Roberts JM and Shankland SJ: Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27Kip1. J Clin Invest 103: 597-604, 1999.